Local recurrent and metastatic malignant melanoma. Long-term results and prognostic factors following percutaneous radiotherapy

Citation
Mh. Seegenschmiedt et al., Local recurrent and metastatic malignant melanoma. Long-term results and prognostic factors following percutaneous radiotherapy, STRAH ONKOL, 175(9), 1999, pp. 450-457
Citations number
37
Categorie Soggetti
Oncology
Journal title
STRAHLENTHERAPIE UND ONKOLOGIE
ISSN journal
01797158 → ACNP
Volume
175
Issue
9
Year of publication
1999
Pages
450 - 457
Database
ISI
SICI code
0179-7158(199909)175:9<450:LRAMMM>2.0.ZU;2-Q
Abstract
Purpose: Radiotherapy (RT) is used as last resort for patients with advance d cutaneous malignant melanoma (MM). Herein our 20-year clinical experience is presented analyzing different endpoints and prognostic factors in patie nts with locally advanced, recurrent or metastatic MM. Patients and Methods: From 1977 to 1995, 2,917 consecutive patients were en tered in the MM registry of our university hospital. RT was indicated in 12 1 patients (56 females. 65 males) for palliation in locally advanced recurr ent and metastatic MM stages UICC IIB to IV. At the time of RT initiation, 11 patients had primary or recurrent lesions which were either not eligible for surgery or had residual disease (R2) after resection of a primary or r ecurrent MM lesion (UICC IIB); 57 patients had lymph node (n = 33) or in-tr ansit metastases (n = 24) (UICC III), and 53 had distant organ metastases ( 7 Mla, 46 Mlb) (UICC IV). The time from first diagnosis to on-study RT aver aged overall 19 months (median: 18; range: 3 to 186 months). In 77 patients conventional RT and in 44 patients hypofractionted RT was applied with 2 t o 6 Gy fractions up to a mean total RT dose of 45 (median: 48; range: 20 to 66) Gy. Results: At 3 months follow-up, complete response (CR) was achieved in 7 (6 4%). overall response (CR + PR) in all (100%) UICC IIB patients. in 25 (44% ) and 44 (77%) of 57 UICC III patients, and in 9 (17%) and 26 (49%) of 53 U ICC IV patients. Tumor progression during RT occurred in 25 (21%) patients. Patients with CR survived longer (median: 40 months) than those without CR (median 10 months) (p < 0.01). At the time of evaluation and last FU (Dece mber 31, 1996), 26 patients were still alive: 6 (55%) stage UICC IIB, 17 (3 0%) stage UICC III, and 3 (6%) stage UICC IV patients (p < 0.01). Univariat e analysis revealed following prognostic factors for CR and long-term survi val: UICC stage (p < 0.001), primary location in the head and neck, total R T dose > 40 Gy (all p < 0.05). while age, gender and primary histological s ubtype had no impact. In multivariate analysis, UICC stage was the only ind ependent favorable prognostic factor for achievement of CR and long-term su rvival (p < 0.001) Conclusion: External RT provides effective palliation in advanced UICC stag es. The UICC staging system is a good predictor of initial and long-term tu mor response in metastatic MM. Prospective randomized trials using RT with or with out adjuvant therapy for advanced MM are justified.